Adenosine Receptors and Wound Healing

Bruce N. Cronstein, M.D.
Professor of Medicine, Pathology and Pharmacology, New York University School of Medicine, 550 First Ave., New York, NY 10016

E-mail: cronsb01@med.nyu.edu

Received August 28, 2003; Revised December 5, 2003; Accepted December 21, 2003; Published January 16, 2004

Recent studies have demonstrated that application of topical adenosine A\textsubscript{2A} receptor agonists promotes more rapid wound closure and clinical studies are currently underway to determine the utility of topical A\textsubscript{2A} adenosine receptor agonists in the therapy of diabetic foot ulcers. The effects of adenosine A\textsubscript{2A} receptors on the cells and tissues of healing wounds have only recently been explored. We review here the known effects of adenosine A\textsubscript{2A} receptor occupancy on the cells involved in wound healing.

**KEYWORDS:** Adenosine, adenosine receptor, angiogenesis, inflammation, granulation tissue

**DOMAIN:** inflammation, drug discovery, drug receptor, molecular pharmacology, pharmacology, receptor pharmacology, endothelial function, intracellular signaling, growth and growth factors, cardiovascular biology, medical research, surgery, tissue engineering

**INTRODUCTION**

Wound repair is an essential homeostatic mechanism that involves a series of coordinated and overlapping phases: inflammation, angiogenesis, new tissue generation, and tissue reorganization. Aberrant or inadequate wound repair contributes to the disability suffered by patients with diabetes mellitus and is a major problem for patients suffering from venous insufficiency. Our laboratory has recently discovered that topical application of adenosine A\textsubscript{2A} receptor agonists promotes more rapid wound healing in full-thickness dermal wounds in both normal animals and animals with streptozotocin-induced diabetes mellitus[1]. More recently, Investigational New Drug status has been granted to the highly selective adenosine A\textsubscript{2A} receptor agonist MRE0094 for use in the treatment of poorly healing foot ulcers in diabetics and initial dose-ranging trials of the drug in patients have begun. To better translate this finding to the clinic, we will review the mechanisms by which adenosine receptor agonists affect the cells involved in wound healing and, thus, promote wound healing.

**PHYSIOLOGIC AND PHARMACOLOGIC ROLES OF ADENOSINE**

Adenosine was first recognized as a physiologic regulator of coronary vascular tone by Drury and Szent-Gyorgy in 1929[2], however it was not until 1970 that Sattin and Rall showed that adenosine regulates cell function via occupancy of specific receptors on the cell surface[3]. It is now clear that there are at
least four different subtypes of adenosine receptor, any one or combination of which may be expressed on the cell surface (recently reviewed in [4]). Four adenosine receptors have been cloned and the deduced sequence reveals that all four are members of the large family of 7-transmembrane spanning, G protein coupled receptors. Three of the adenosine receptor subtypes — A₁, A₂A, and A₂B — are highly conserved throughout evolution (80–95% sequence homology) whereas A₃ receptors vary significantly among species. In general, A₁ receptors are coupled to pertussis toxin-inhibited Gᵢ coupled signal transduction proteins or directly to ion channels whereas A₂ receptors (A₂A and A₂B) are coupled to Gₛₐₐₐ-linked receptors and stimulate adenylyl cyclase and cAMP accumulation. Adenosine receptors or receptor-mediated effects have been demonstrated in virtually every tissue or organ examined. Some of the more prominent physiologic or pharmacologic effects mediated by adenosine receptors include: neurotransmission (A₁ and A₂A receptors, the CNS effects of caffeine are thought to result from adenosine receptor antagonism); modulation of cardiac conduction (A₁ receptors, intravenous preparations of adenosine are licensed for clinical use for the treatment of supraventricular tachycardia); coronary vasodilation (A₂A receptors, infusions of adenosine are licensed for clinical use as a coronary vasodilator for pharmacologic stress testing); regulation, indirectly, of airway tone (A₂B receptors); inhibition of inflammation (mediates the anti-inflammatory effects of low-dose methotrexate, the most commonly used second-line agent for the treatment of rheumatoid arthritis (reviewed in [5,6]). Our laboratory first demonstrated that adenosine modulates neutrophil function via interaction with A₁ and A₂ receptors and, when released from cells in increased concentration, inhibits inflammation (reviewed in [6]). In many tissues and cell types, A₁ and A₂A receptors have opposing actions not only on cAMP levels but on function as well (cf. [7,8]). More recently, as noted above, topical application of an adenosine A₂A receptor agonist has been shown to promote wound healing, a process dependent upon the proliferation of blood vessels, in both normal mice and diabetic rats[1].

THE EFFECTS OF ADENOSINE A₂A RECEPTOR AGONISTS ON WOUND HEALING

Our lab has recently reported that topical application of an adenosine A₂A receptor agonist increases the rate at which wounds close[1]. That adenosine A₂A receptors were involved in this pharmacologic effect was demonstrated by the observation that a specific adenosine A₂A receptor antagonist, but not antagonists at other adenosine receptors, reversed the effect of the selective A₂A receptor agonist CGS21680 in these studies. Treatment of wounds with an adenosine receptor agonist promoted fibroblast migration in vitro and in the adenosine receptor agonist-treated mice there was an increase in matrix and fibroblast infiltration into the wounds[1]. More recent studies demonstrate that a more highly selective adenosine A₂A receptor agonist, MRE0094, is a more potent promoter of wound healing than recombinant platelet derived growth factor (becaplermin[9]). The role of adenosine A₂A receptors in the promotion of wound healing was more fully confirmed by the observation that a selective adenosine A₂A receptor agonist promotes wound healing in wild type but not A₂A receptor knockout mice[6]. In these studies, there was a marked increase in the number of blood vessels in the healing wounds of wild type mice treated with the adenosine A₂A receptor agonist as compared to untreated controls. Absence of A₂A receptors was associated with disorganized granulation tissue although wound closure was not delayed in the knockout mice. In contrast to the work showing that the adenosine A₂A receptor promotes wound healing, Sun and colleagues observed that N⁶-cyclopentyladenosine, a relatively selective A₁ receptor agonist, promotes wound healing and, interestingly, hair growth[10]. In this study, there was no confirmation that the high concentrations of the agonist used were indeed selective for A₁ receptors or whether the phenomenon was mediated by adenosine acting at A₂A receptors. Interestingly, more recent studies have suggested that the capacity of minoxidil to stimulate hair growth is mediated by ligation of adenosine A₁ receptors by increased concentrations of endogenously released adenosine[11].
THE EFFECTS OF ADENOSINE ON INFLAMMATION

As noted above, inflammation is the first step in wound healing. During this phase of tissue repair, necrotic debris is eliminated and bacterial superinfection is prevented by an influx of inflammatory cells, primarily neutrophils at the outset with a predominance of monocytes and lymphocytes later during the course of wound healing. In addition to clearing debris, inflammatory cells release a variety of agents that stimulate the later stages in wound healing. In some pathologic settings, persistent or overly exuberant inflammation may interfere with wound healing. Our laboratory first demonstrated that adenosine, acting at a specific extracellular receptor, inhibits stimulated neutrophil function, release of reactive oxygen species[12,13]. In subsequent studies, it was demonstrated that adenosine receptor occupancy inhibits neutrophil phagocytosis, stimulated neutrophil adhesion to endothelial cells and matrix proteins, and neutrophil-mediated endothelial cell injury[7,14,15]. Early studies demonstrated, by pharmacologic means, that neutrophils express at least two different types of adenosine receptor, one of which (A<sub>2</sub> receptors) mediates the inhibition of neutrophil function described above and the other (A<sub>1</sub> receptors), when occupied, promotes neutrophil chemotaxis, phagocytosis, and adhesion to vascular endothelial cells[7,14,15,16,17]. These observations have now been confirmed and expanded upon by a large number of laboratories (reviewed in [18]) and it is clear that A<sub>2A</sub> receptors are the A<sub>2</sub> receptors responsible for the suppression of neutrophil function. Although the actions of adenosine A<sub>2A</sub> receptor occupancy on neutrophil function have generally been ascribed to cAMP (cf. [19]) this signal transduction mechanism appears to hold only in primed (tumor necrosis factor- or endotoxin-stimulated) neutrophils. In contrast, in unprimed neutrophils, the effects of adenosine A<sub>2</sub> receptor occupancy modulates neutrophil behavior by a cAMP-protein kinase A-independent mechanism involving activation of a plasma membrane-associated protein phosphatase[20,21].

In addition to its effects on neutrophil function, adenosine — acting at its receptors — also modulates macrophage function. In contrast to neutrophils, both A<sub>2A</sub> and A<sub>3</sub> adenosine receptors appear to be involved in suppression of inflammatory functions of macrophages and there are species-related differences in the effects of these adenosine receptors on macrophage function. Adenosine, acting at A<sub>2A</sub> receptors, inhibits generation of reactive oxygen species, phagocytosis, cytokine release (TNF, C2, tissue factor/procoagulant), and increases plasminogen activator and IL-10 production (reviewed in [18]). Similar effects have been described for the A<sub>1</sub> receptor, although the A<sub>3</sub> receptor contribution to adenosine-mediated modulation of inflammation is most notable in cells from mice and is often not demonstrable in human cells.

Adenosine is released from cells and tissues following a variety of insults, e.g., ischemia or inflammation, and presumably is derived from the dephosphorylation of ATP either within the cell or extracellularly[22,23,24,25]. Previous studies, using relatively nonselective adenosine receptor antagonists, have shown that endogenous adenosine regulates inflammation[26] and more recent studies have demonstrated that absence of adenosine A<sub>2A</sub> receptors increases inflammatory injury[27].

Clearly the use of adenosine or adenosine analogues for the treatment of inflammation has been contemplated and adenosine A<sub>2A</sub> receptor agonists have been shown to be useful in several models of inflammation[28,29,30,31,32,33]. Nonetheless, fear of the many potential physiologic and pharmacologic effects of adenosine receptor agonists has limited the utility of this approach to suppressing inflammation. Another approach to ligation of adenosine receptors as an anti-inflammatory agent is to promote endogenous adenosine release. The first demonstration that existing anti-inflammatory therapies might make use of endogenous adenosine was reported in 1991 when it was shown, based on in vitro experiments, that low-dose methotrexate therapy, the most commonly used and effective second-line therapy for the treatment of rheumatoid arthritis, induces an increase in adenosine release from injured cells and the adenosine so released inhibits inflammation[34]. Subsequent studies provided support for the hypothesis that adenosine mediates the anti-inflammatory effects of methotrexate provided by observations in an in vivo model of inflammation in which adenosine A<sub>2</sub> receptor antagonists and adenosine deaminase reversed the anti-inflammatory effects of methotrexate in mice[35]. In further animal studies, it has been observed that a commonly used adenosine receptor antagonist, caffeine,
reverses the anti-inflammatory effects of methotrexate in the adjuvant arthritis model of inflammation[36] and coffee ingestion (presumably with caffeine) was recently shown to interfere with the anti-inflammatory actions of methotrexate in patients as well[37], an observation that suggests that avoidance of caffeine may enhance the therapeutic effects of methotrexate. In other studies, sulfasalazine, another commonly used second-line agent for the therapy of inflammatory arthritis, shares a mechanism of action with methotrexate; sulfasalazine also promotes the release of adenosine from inflamed cells and tissues and the adenosine released occupies $A_2$ receptors on inflammatory cells to diminish inflammation[38]. On the basis of these findings and confirmatory studies from other laboratories, specific enzyme (adenosine kinase) inhibitors have been developed that promote adenosine release and suppress inflammation[39,40,41,42].

Interestingly, FK506, a potent and commonly used immunosuppressive agent, has also been reported to inhibit adenosine kinase and adenosine is thought to mediate its effects on acute inflammation[43]. None of the agents described above have been studied in the promotion of wound healing, nor have there been reports that administration of either sulfasalazine or methotrexate interferes or promotes wound healing.

**THE EFFECT OF ADENOSINE RECEPTOR OCCUPANCY ON ANGIogenesis AND endothelial CELL FUNCTION**

Previous reports document, by RT-PCR, that cultured human endothelial cells (umbilical vein) express message for all four adenosine receptors[1], although more recent studies document only $A_{2A}$ and $A_{2B}$ receptor message in human microvascular endothelial cells (Khoa, in press). Although the functional effects of ligation of all of the adenosine receptors on endothelial cells have not been fully explored, it is now clear that adenosine receptor occupancy promotes several potential angiogenic effects when studied in vitro. These studies, from different laboratories, demonstrate that adenosine, acting at specific $A_2$ receptors, promotes endothelial cell proliferation, migration, and growth factor (VEGF) production[44,45,46,47,48,49]. Moreover, in a recent study it was shown that the effect of adenosine on endothelial cell proliferation is mediated by $A_{2A}$ receptors and that cAMP is probably not the second messenger for this phenomenon[49]. Bouma and co-workers have also reported that adenosine, possibly acting at $A_2$ receptors, diminishes expression of IL-8, a potent angiogenic agent, by stimulated endothelial cells[50]. In contrast, others have reported that the cells responsible for the most abundant IL-8 secretion
at inflamed sites, macrophage/monocytes, are unaffected by adenosine receptor agonists in their capacity to secrete this angiogenic cytokine[51,52]. Adenosine, acting at A2A and A3 receptors, inhibits tissue factor expression on endothelial cells[53] and promotes NO release by endothelial cells[54]. Recent studies suggest that adenosine A2B receptor occupancy is responsible for promotion of retinal angiogenesis[55,56] although these results may not apply to other vascular beds or to angiogenesis in wounds. Thus, it was recently reported[57] that mice with genetically disrupted A2A receptors (knockouts) form significantly fewer microvessels in healing wounds and in response to mechanical trauma (formation of an air pouch[57]). Furthermore, application of an A2A receptor agonist to wounds increases microvessel formation as compared to vehicle-treated mice, observations that provide the first in vivo evidence that adenosine A2A receptor occupancy promotes angiogenesis. Further studies indicate that the angiogenic effects of adenosine A2A receptor occupancy are mediated both directly on endothelial cells (increased endothelial cell migration and microvascular endothelial cell VEGF production) ([1]; Khoa et al., in press) and indirectly via promotion of VEGF production by macrophages[58]. Similar to other angiogenic agents, adenosine — acting at A2A receptors — is a potent vasodilator that is also thought to mediate reactive hyperemia in skeletal muscle and the heart. Thus, adenosine, acting via A2A receptors, promotes angiogenesis both directly and indirectly and does so, notably, both in vitro and in vivo.

CONCLUSION

Recent studies indicate that adenosine A2A receptor agonists are useful in promoting more rapid wound healing in mice. Beneficial effects of adenosine A2A receptor agonists on all aspects of wound healing — inflammation, angiogenesis, and tissue regeneration — have been observed and probably contribute to promotion of wound closure in both normal healthy mice and diabetic animals as well. There remains an unmet need for agents that will promote wound healing in patients with diabetes and other conditions associated with poor wound healing and it is possible that topical adenosine receptor agonists may help fill this need.

ACKNOWLEDGMENTS

This work was supported by grants from the National Institutes of Health (AR41911, GM56268, AA13336); a grant from King Pharmaceuticals Inc.; the General Clinical Research Center (M01RR00096) and by the Kaplan Cancer Center.

REFERENCES

1. Montesinos, M.C., Gadangi, P., Longaker, M., Sung, J., Levine, J., Nilsen, D., Reibman, J., Li, M., Jiang, C.K., Hirschhorn, R., Recht, P.A., Ostad, E., Levin, R.I., and Cronstein, B.N. (1997) Wound healing is accelerated by agonists of adenosine A2 (G alpha s-linked) receptors. J. Exp. Med. 186, 1615–1620.
2. Drury, A.N. and Szent-Gyorgi, A. (1929) The physiological activity of adenine compounds with special reference to their action upon the mammalian heart. J. Physiol. 68, 213–237.
3. Sattin, A. and Rall, T.W. (1970) The effect of adenosine and adenine nucleotides on the cyclic adenosine-3',5'-phosphate content of guinea pig cerebral cortex slices. Mol. Pharmacol. 6, 13–23.
4. Olah, M.E. and Stiles, G.L. (1995) Adenosine receptor subtypes: characterization and therapeutic regulation. Annu. Rev. Pharmacol. Toxicol. 35, 581–606.
5. Fredholm, B.B., Arslan, G., Hallldner, L., Kull, B., Schulte, G., and Wasserman, W. (2000) Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch. Pharmacol. 362, 364–374.
6. Montesinos, M.C. and Cronstein, B.N. (2001) Role of P1 receptors in inflammation. In Handbook of Experimental Pharmacology. Vol. 151/II. Purinergic and Pyrimidinergic Signaling II. Cardiovascular, Respiratory, Immune, Metabolic and Gastrointestinal Tract Function. Abbracchio, M.P. and Williams, M., Eds. Springer-Verlag, Berlin. pp. 303–321.
7. Salmon, J.E. and Cronstein, B.N. (1990) Fcgamma receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy: A1 receptors are stimulatory and A2 receptors are inhibitory. J. Immunol. 145, 2235–2240.
8. Londos, C., Cooper, D.M.F., and Wolff, J. (1980) Subclasses of external adenosine receptors. Proc. Natl. Acad. Sci. U.S.A. 77, 2551–2554.
9. Victor-Vega, C., Desai, A., Montesinos, M., and Cronstein, B. (2002) Adenosine A2A agonists promote more rapid wound healing than recombinant human platelet derived growth factor (PDGF). Inflammation 26, 19–24.
10. Sun, L.L., Xu, L.L., Nielsen, T.B., Rhee, P., and Burris, D. (1999) Cylcopentyladenosine improves cell proliferation, wound healing, and hair growth. J. Surg. Res. 87, 14–24.
11. Li, M., Murabayashi, A., Nakaya, Y., Fukui, K., and Arase, S. (2001) Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J. Invest. Dermatol. 117, 1594–1600.
12. Cronstein, B.N., Rosenstein, E.D., Kramer, S.B., Weissmann, G., and Hirschchorn, R. (1985) Adenosine: a physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils. J. Immunol. 135, 1366–1371.
13. Cronstein, B.N., Kramer, S.B., Weissmann, G., and Hirschchorn, R. (1983) Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. J. Exp. Med. 158, 1160–1177.
14. Cronstein, B.N., Levin, R.I., Belanoff, J., Weissmann, G., and Hirschchorn, R. (1986) Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J. Clin. Invest. 78, 760–770.
15. Cronstein, B.N., Levin, R.I., Philips, M.R., Hirschchorn, R., Abramson, S.B., and Weissmann, G. (1992) Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J. Immunol. 148, 2201–2206.
16. Cronstein, B.N., Duguma, L., Nicholls, D., Hutchison, A., and Williams, M. (1990) The adenosine/neutrophil paradox resolved. Human neutrophils possess both A1 and A2 receptors which promote chemotaxis and inhibit O2- generation, respectively. J. Clin. Invest. 85, 1150–1157.
17. Rose, F.R., Hirschchorn, R., Weissmann, G., and Cronstein, B.N. (1988) Adenosine promotes neutrophil chemotaxis. J. Exp. Med. 167, 1186–1194.
18. Cronstein, B.N. (1998) Adenosine and its receptors during inflammation. In Molecular and Cellular Basis of Inflammation. Serhan, C.N. and Ward, P.A., Eds. Humana Press, Totowa, NJ. pp. 259–274.
19. Sullivan, G.W., Rieger, J.M., Scheld, W.M., Macdonald, T.L., and Linden, J. (2001) Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A2A receptor agonists. Br. J. Pharmacol. 132, 1017–1026.
20. Cronstein, B.N., Haines, K.A., Kolasiński, S.L., and Reibman, J. (1991) Gs linked receptors (beta-adrenergic and adenosine A2) uncouple chemoattractant receptors from G proteins. Clin. Res. 39, 343A.
21. Revan, S., Montesinos, M.C., Naime, D., Landau, S., and Cronstein, B.N. (1996) Adenosine A2 receptor occupancy regulates stimulated neutrophil function via activation of a serine/threonine protein phosphatase. J. Biol. Chem. 271, 17114–17118.
22. Morabito, L., Montesinos, M.C., Schreibman, D.M., Balter, L., Thompson, L.F., Resta, R., Carlin, G., Huie, M.A., and Cronstein, B.N. (1998) Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5’-nucleotidase-mediated conversion of adenine nucleotides. J. Clin. Invest. 101, 295–300.
23. Cronstein, B.N., Van de Stouwe, M., Druska, L., Levin, R.I., and Weissmann, G. (1994) Nonsteroidal antiinflammatory agents inhibit stimulated neutrophil adhesion to endothelium: adenosine dependent and independent mechanisms. Inflammation 18, 323–335.
24. Newby, A.C., Holmquist, C.A., Illingworth, J., and Pearson, J.D. (1983) The control of adenosine concentration in polymorphonuclear leucocytes, cultured heart cells and isolated perfused heart from the rat. Biochem. J. 214, 317–323.
25. Pearson, J.D. and Gordon, J.L. (1979) Vascular endothelial and smooth muscle cells in culture selectively release adenine nucleotides. Nature 281, 384–386.
26. Rosengren, S., Arfors, K.E., and Proctor, K.G. (1991) Potentiation of leukotriene B4-mediated inflammatory response by the adenosine antagonist, 8-phenyl theophylline. Int. J. Microcirc. Clin. Exp. 10, 345–357.
27. Ohta, A. and Sitkovsky, M. (2001) Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414, 916–920.
28. Okusa, M.D., Linden, J., Huang, L., Rieger, J.M., Macdonald, T.L., and Huynh, L.P. (2000) A2A adenosine receptor-mediated inhibition of renal injury and neutrophil adhesion. Am. J. Physiol. Renal Physiol. 279, F809–818.
29. Sullivan, G.W., Linden, J., Baster, B.L., and Scheld, W.M. (1999) Neutrophil A2A adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with the type IV phosphodiesterase inhibitor, rolipram. J. Infect. Dis. 180, 1550–1560.
30. Okusa, M.D., Linden, J., Macdonald, T., and Huang, L. (1999) Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney. Am. J. Physiol. 277, F404–412.
31. Ross, S.D., Tribble, C.G., Linden, J., Gangemi, J.J., Lanpher, B.C., Wang, A.Y., and Kron, I.L. (1999) Selective adenosine-A2A activation reduces lung reperfusion injury following transplantation. J. Heart Lung Transplant. 18,
994–1002.

32. Peirce, S.M., Skalak, T.C., Rieger, J.M., Macdonald, T.L., and Linden, J. (2001) Selective A(2A) adenosine receptor activation reduces skin pressure ulcer formation and inflammation. Am. J. Physiol. Heart Circ. Physiol. 281, H67–74.

33. McPherson, J.A., Barringhaus, K.G., Bishop, G.G., Sanders, J.M., Rieger, J.M., Hesselbacher, S.E., Gimple, L.W., Powers, E.R., Macdonald, T., Sullivan, G., Linden, J., and Sarembock, I.J. (2001) Adenosine A(2A) receptor stimulation reduces inflammation and neointimal growth in a murine carotid figation model. Arterioscler. Thromb. Vasc. Biol. 21, 791–796.

34. Cronstein, B.N., Eberle, M.A., Gruber, H.E., and Levin, R.I. (1991) Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc. Natl. Acad. Sci. U.S.A. 88, 2441–2445.

35. Cronstein, B.N., Naime, D., and Ostad, E. (1993) The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Invest. 92, 2675–2682.

36. Montesinos, C., Yap, J.S., Desai, A., Posadas, I., McMorrow, C.T., and Cronstein, B.N. (2000) Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine. Evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum. 43, 656–663.

37. Silke, C., Murphy, M.S., Buckley, T., Bussel, S., Molloy, M.G., and Phelan, M. (2001) The effects of caffeine ingestion on the efficacy of methotrexate. Rheumatology (Oxford) 40(Suppl. 1), 34.

38. Gadangi, P., Longaker, M., Naime, D., Levin, R.I., Recht, P.A., Montesinos, M.C., Buckley, M.T., Carlin, G., and Cronstein, B.N. (1996) The antiinflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J. Immunol. 156, 1937–1941.

39. Cronstein, B.N., Naime, D., and Firestein, G.S. (1995) The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine. Arthritis Rheum. 38, 1040–1045.

40. Firestein, G.S., Bullough, D., Erion, M., Ugarkar, B., Browne, G., Barankiewicz, J., Gruber, H., and Mullane, K. (1993) Adenosine regulating agents: a novel approach to acute inflammation and inflammatory arthritis. Clin. Res. 41, 170A.

41. Firestein, G.S., Boyle, D., Bullough, D.A., Gruber, H.E., Sajjadi, F.G., Montag, A., Sambol, B., and Mullane, K. (1994) Protective effect of an adenosine kinase inhibitor in septic shock. J. Immunol. 152, 5853–5859.

42. Rosengren, S., Bong, G.W., and Firestein, G.S. (1995) Anti-inflammatory effects of an adenosine kinase inhibitor: decreased neutrophil accumulation and vascular leakage. J. Immunol. 154, 5444–5451.

43. Hwang, K.K., Hall, C.S., Spielman, W.S., and Sparks, H.V. (2001) FK506 promotes adenosine release from endothelial cells via inhibition of adenosine kinase. Eur. J. Pharmacol. 425, 85–93.

44. Fischer, S., Sharma, H.S., Karliecek, G.F., and Schaper, W. (1995) Expression of vascular permeability factor/vascular endothelial growth factor in pig cerebral microvascular endothelial cells and its upregulation by adenosine. Mol. Brain Res. 28, 141–148.

45. Takagi, H., King, G.L., Robinson, G.S., Ferrara, N., and Aiello, L.P. (1996) Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and endothelial cells. Invest. Ophthalmol. Vis. Sci. 37, 2165–2176.

46. Takagi, H., King, G.L., Ferrara, N., and Aiello, L.P. (1996) Hypoxia regulates vascular endothelial growth factor receptor KDR/Flk gene expression through adenosine A2 receptors in retinal capillary endothelial cells. Invest. Ophthalmol. Vis. Sci. 37, 1311–1321.

47. Meining, C.J., Schelling, M.E., and Granger, H.J. (1988) Adenosine and hypoxia stimulate proliferation and migration of endothelial cells. Am. J. Physiol. 255, H554–H562.

48. Ethier, M.F., Chander, V., and Dobson, J.G., Jr. (1993) Adenosine stimulates proliferation of human endothelial cells in culture. Am. J. Physiol. 265, H1131–H1138.

49. Sextl, V., Mancusi, G., Baumgartner-Parzer, S., Schutz, W., and Freissmuth, M. (1995) Stimulation of human umbilical vein endothelial cell proliferation by A2-adenosine and beta 2-adrenoceptors. Br. J. Pharmacol. 114, 1577–1586.

50. Bouma, M.G., van den Wildenberg, F.A.J.M., and Buurman, W.A. (1996) Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am. J. Physiol. 39, C522–C529.

51. Sajjadi, F.G., Takabayashi, K., Foster, A.C., Domingo, R.C., and Firestein, G.S. (1996) Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. J. Immunol. 156, 3435–3442.

52. Feoktistov, I. and Biaggioni, I. (1995) Adenosine A2B receptors evoke interleukin-8 secretion in human mast cells. An enprophyline-sensitive mechanism with implications for asthma. J. Clin. Invest. 96, 1979–1986.

53. Deguchi, H., Takeya, H., Urano, H., Gabazza, E.C., Zhou, H., and Suzuki, K. (1998) Adenosine regulates tissue factor expression on endothelial cells. Thromb. Res. 91, 57–64.

54. Li, J., Fenton, R.A., Wheeler, H.B., Powell, C.C., Peyton, B.D., Cutler, B.S., and Dobson, J.G., Jr. (1998) Adenosine A2a receptors increase arterial endothelial cell nitric oxide. J. Surg. Res. 80, 357–364.

55. Grant, M.B., Davis, M.I., Caballero, S., Feoktistov, I., Biaggioni, I., and Belardinelli, L. (2001) Proliferation, migration, and ERK activation in human retinal endothelial cells through A(2B) adenosine receptor stimulation. Invest. Ophthalmol. Vis. Sci. 42, 2068–2073.
56. Grant, M.B., Tarnuzzer, R.W., Caballero, S., Ozeck, M.J., Davis, M.I., Spoerri, P.E., Feoktistov, I., Biaggioni, I., Shryock, J.C., and Belardinelli, L. (1999) Adenosine receptor activation induces vascular endothelial growth factor in human retinal endothelial cells. *Circ. Res.* **85**, 699–706.

57. Montesinos, M., Chen, J.-F., Desai, A., Yee, H., Jacobson, M., Schwarzschild, M., Fink, J., and Cronstein, B. (2002) Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A2A receptors. *Am. J. Pathol.* **160**, 2000–2009.

58. Leibovich, S., Chen, J.-F., Belem, P., Elson, G., Rosania, A., Ramanathan, M., Montesinos, M., Jacobson, M., Schwarzschild, M., Fink, J., and Cronstein, B. (2002) Synergistic up-regulation of vascular endothelial growth factor (VEGF) expression in murine macrophages by adenosine A2A receptor agonists and endotoxin. *Am. J. Pathol.* **160**, 2231–2244.

This article should be referenced as follows:

Cronstein, B.N. (2004) Adenosine receptors and wound healing. *TheScientificWorldJOURNAL* **4**, 1–8.

**Handling Editor:**

Edward J. Geotzl, Principal Editor for Inflammation — a domain of *TheScientificWorldJOURNAL*.

**BIOSKETCH**

**Dr. Cronstein** is Professor of Medicine, Pathology and Pharmacology at New York University School of Medicine where he has been on the faculty since 1980. Dr. Cronstein is currently Director of the Division of Clinical Pharmacology of the Department of Medicine and Associate Chairman of Medicine for Research. Dr. Cronstein first demonstrated that the purine autocoid adenosine is a potent suppressor of inflammation. In subsequent studies, Dr. Cronstein and his colleagues demonstrated that the anti-inflammatory effects of adenosine are mediated by specific cell surface receptors. Following this initial demonstration, Dr. Cronstein showed that adenosine is released by injured cells and acts, therefore, as a feedback suppressor of inflammation. More recently, Dr. Cronstein and his colleagues have demonstrated that adenosine mediates the anti-inflammatory actions of low-dose methotrexate, the most commonly used and effective second-line agent for the treatment of rheumatoid arthritis, using both *in vitro* and *in vivo* models. Dr. Cronstein’s laboratory has continued to explore the role of adenosine and its receptors in the treatment of human disease and has made the original observation that topical application of adenosine A2A receptor agonists promotes wound healing in murine models. This discovery is now undergoing translation to the clinic and, following granting of Investigational New Drug status, an adenosine A2A receptor agonist has recently entered early clinical trials for the treatment of diabetic foot ulcers.